CClinicalTrials.gg
CompletedNCT07649577Updated Jun 16, 2026

Generative AI for Medication Counselling and Adherence in Community Pharmacies

An interventional study of pharmacist-supervised AI-assisted medication counseling in Hypertension, Diabetes Mellitus and Dyslipidemias, sponsored by University of Petra. Completed at 1 site in Jordan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by University of Petra · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2026, registered Jun 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Medication counseling within community pharmacies is crucial for managing chronic diseases, yet significant challenges regarding correctness and completeness remain in Jordan. Although generative artificial intelligence (AI) can be utilized for patient education, there is a lack of research on clinical impact and safety of AI in medication counseling conducted by pharmacists in real-world practice. The aim of this study is to evaluate the effect of pharmacist-supervised AI-assisted medication counseling on the correctness and completeness of counseling information and 30-day medication adherence among patients in Jordanian community pharmacies.

Read the detailed description

Materials and Methods: This pragmatic, two-arm cluster randomized controlled trial enrolled 136 adult patients across 16 community pharmacies in Jordan (8 clusters per arm). Pharmacists in the intervention arm used a standardized prompt strategy with ChatGPT® to generate counseling drafts, which were then verified and edited before delivery. The control arm provided usual counseling. Co-primary outcomes were correctness and completeness of counseling information (percentage scores based on blinded transcript analysis). Secondary outcomes included 30-day medication adherence (General Medication Adherence Scale [GMAS]), immediate patient understanding, and satisfaction. Data were analyzed using mixed-effects linear and logistic regression models.

02

Conditions studied

  • Hypertension
  • Diabetes Mellitus
  • Dyslipidemias
  • Cardiovascular Diseases
  • Pulmonary Disease, Chronic Obstructive
  • Asthma
  • Chronic Disease
03

In context

Hypertension

6,687 studies on the registry are indexed under Hypertension; 964 are open to participants now.

This study's enrollment of 136 is above the median of 90 across 4,994 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of Petra is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Patient Eligibility Criteria

Inclusion Criteria:

Adults aged 18 years or older. Presenting with a new prescription or a refill for a chronic medication requiring counseling within one of the following classes: antihypertensives, oral antidiabetics, lipid-lowering agents, anticoagulants, or inhaled maintenance therapies.

Willing and able to provide informed consent.

Exclusion Criteria:

Presence of acute infections. Diagnosis of psychiatric disorders or oncological conditions. Presence of severe acute illness requiring urgent medical referral. Cognitive impairment precluding informed consent. Hearing or communication barriers that prevent interview completion without the presence of a caregiver.

Inability to provide a follow-up phone number for the 30-day adherence assessment.

Pharmacy and Pharmacist (Cluster) Eligibility Criteria

Inclusion Criteria:

Pharmacies legally registered in Jordan, providing routine prescription dispensing services, having at least one licensed pharmacist available during recruitment hours, and agreeing to participate for the full trial period.

Licensed pharmacists with a minimum of 2 years of clinical experience, working in participating pharmacies, providing direct patient counseling, and consenting to take part in the study.

Exclusion Criteria:

Pharmacies that are already using structured AI-assisted counseling tools as part of their routine practice.

Pharmacists on temporary placement for less than one month. Pharmacists not involved in patient-facing counseling.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Active comparator
    Intervention arm procedures

    For all eligible patients in the intervention arm, the pharmacist performed the standard patient assessment and determined which medicine(s) needed counselling. Then, the pharmacist input a prompt in a de-identified format into ChatGPT®. The prompt was a request for an easy-to-understand counselling document with information regarding the indications for the medication, dosage, schedule, route, course, missed doses, possible side effects, important precautions, storage, and advice on taking the medicine as prescribed (Appendix A). The pharmacist ensured that the content generated by the AI was accurate and clear, making corrections where necessary, and then gave verbal counselling to the patient.

    Other: pharmacist-supervised AI-assisted medication counseling

  • No intervention
    Control arm procedures

    Pharmacies randomized to the control arm continued to provide usual medication counselling according to their standard routine practice, without access to the AI prompt templates or study AI workflow. Control pharmacists used their usual professional references, as would occur in routine care, but they were not trained in or asked to use ChatGPT® during the trial period.

Interventions

  • Otherpharmacist-supervised AI-assisted medication counseling

    For all eligible patients in the intervention arm, the pharmacist performed the standard patient assessment and determined which medicine(s) needed counselling. Then, the pharmacist input a prompt in a de-identified format into ChatGPT®. The prompt was a request for an easy-to-understand counselling document with information regarding the indications for the medication, dosage, schedule, route, course, missed doses, possible side effects, important precautions, storage, and advice on taking the medicine as prescribed (Appendix A). The pharmacist ensured that the content generated by the AI was accurate and clear, making corrections where necessary, and then gave verbal counselling to the patient. The AI output was never provided to the patients without pharmacist evaluation. It is worth noting that pharmacists could also reject the AI output as inaccurate, insufficient, hazardous, and inappropriate altogether. Reproducibility was ensured through documenting the date and time, prompt te

    Also known as: Intervention arm procedures

06

What researchers measure

Primary outcomes

  1. Percentage of Applicable Counseling Domains Provided Correctly

    Defined as the proportion of clinically applicable counseling domains communicated accurately during the encounter, compared with a medication-specific reference sheet. Scored on a 0-100 scale, calculated as (Number of applicable domains correctly informed / Total number of applicable domains) x 100.Correctness score= (Number of applicable domains

    Time frame: day 0

  2. Percentage of Essential Counseling Domains Addressed

    Defined as the proportion of essential counseling domains that were addressed during the encounter. Scored on a 0-100 scale, calculated as (Number of applicable domains addressed / Total number of applicable domains) x 100.

    Time frame: Day 0

Secondary outcomes

  1. Number of Counseling Deficiencies Categorized by Clinical Severity

    The frequency of omitted or incorrect counseling information, independently assessed by a panel of pharmacists using a 3-point scale: Low Severity (minor wording issues), Moderate Severity (errors leading to sub-therapeutic effects), and High Severity (errors with high potential for significant patient harm).

    Time frame: Day 0

  2. Score on the General Medication Adherence Scale (GMAS)

    Medication adherence assessed via telephone follow-up using the continuous total score from the General Medication Adherence Scale (GMAS). Higher scores indicate better medication adherence.

    Time frame: 30 Days Post-Encounter

  3. Number of Participants Achieving Good Adherence

    The number of participants meeting the validated threshold for "good adherence" based on their GMAS survey responses.

    Time frame: 30 Days Post-Encounter

  4. Total Score on the Immediate Patient Understanding (Teach-Back) Assessment

    A brief interviewer-administered understanding assessment based on teach-back principles. Scores range from 0 to 4, with higher scores indicating a better understanding of the medication.

    Time frame: Day 0

  5. Total Score on the Patient Satisfaction Questionnaire

    A questionnaire covering clarity, usefulness, confidence, and overall satisfaction. Total scores range from 5 to 25, with higher scores indicating greater patient satisfaction.

    Time frame: Day 0

  6. Time Spent on Face-to-Face Counseling

    Total face-to-face counseling time measured in minutes using audio timestamps from the start of counseling to completion.

    Time frame: Day 0

  7. Number of Encounters Based on AI Output Acceptance Level

    The proportion of encounters in which the AI-generated counseling output was fully accepted, edited before delivery, or rejected outright by the pharmacist.

    Time frame: Day 0

  8. Number of AI-Related Discrepancies Identified

    The frequency of detected AI inaccuracies prior to counseling, such as omitted counseling points, overly technical wording, or incomplete missed-dose advice.

    Time frame: Day 0

  9. Number of Clinical Near Misses and Safety Incidents

    The number of encounters featuring a "near miss" (an AI error identified and corrected by the pharmacist before reaching the patient) or an "incident" (inaccurate information that actually reached the patient).

    Time frame: Day 0

07

Study locations

1 site
  • Petra University
    Amman, Jordan
08

References and documents

Publications

  • Abdel-Qader, D. H., Al Meslamani, A. Z., Lewis, P. J., & Hamadi, S. (2021). Incidence, nature, severity, and causes of dispensing errors in community pharmacies in Jordan. International journal of clinical pharmacy, 43(1), 165-173. https://doi.org/10.1007/s11096-020-01126-w Abdel-Qader, D. H., et al. (2024). A comprehensive analysis of public satisfaction: Community pharmacists' pandemic preparedness in Jordan. Journal of Applied Pharmaceutical Science, 14(8), 160-168. Abdel-Qader, D. H., et al. (2025). Drug-Drug interaction management among pharmacists in Jordan: A national comparative survey. Pharmacy, 137. https://doi.org/10.3390/pharmacy13050137 Abu Hammour, K., et al. (2023). ChatGPT in pharmacy practice: A cross-sectional exploration of Jordanian pharmacists' perception, practice, and concerns. Journal of Pharmaceutical Policy and Practice, 16(1), 115. Ali, S., Shimels, T., & Bilal, A. I. (2019). Assessment of patient counseling on dispensing of medicines in outpatient pharmacy of Tikur-Anbessa Specialized Hospital, Ethiopia. Ethiopian journal of health sciences, 29(6), 727. Campbell, M. K., et al. (2012). Consort 2010 statement: Extension to cluster randomised trials. BMJ, 345. Chan, A.-W., et al. (2015). SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Revista Panamericana de Salud Pública, 38, 506-514. Elayeh, E. R., et al. (2019). Use of secret simulated patient followed by workshop based education to assess and improve inhaler counseling in community pharmacy in Jordan. Pharmacy Practice (Granada), 17(4). Fattah, F. H., et al. (2025). Comparative analysis of ChatGPT and Gemini (Bard) in medical inquiry: A scoping review. Frontiers in digital health, 7, 1482712. FIP, I. P. F. (2021). Medication review and medicines use review: A toolkit for pharmacists Colophon. FIP, I. P. F. (2025). An artificial intelligence toolkit for pharmacy: An introduction and resource guide for pharmacists. (March). Hammad, E. A., et al. (2022). Feasibi

Study documents

  • Protocol and statistical analysis plan · Jun 9, 2026

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07649577
Lead sponsor
University of Petra
Responsible party
Derar H. Abdel-Qader (Clinical Professor, University of Petra) — Principal investigator
First posted
Jun 16, 2026
Start date
Jan 1, 2026
Primary completion
Mar 30, 2026
Completion
Mar 30, 2026
Last update
Jun 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion